About This Field Guide

What Long Island Peptides is

Long Island Peptides is an independent editorial field guide to the published research on four peptides studied for the growth hormone (GH) axis: CJC-1295, CJC-1295/Ipamorelin, ipamorelin, and tesamorelin, with CJC-1295 as the lead compound. The guide exists to make a genuinely mixed body of evidence — some of it rigorous and FDA-reviewed, some of it thin and decades-old, some of it entirely anecdotal — legible to a curious, careful reader.

The organizing idea is mechanistic: two of these compounds work through the GHRH receptor, one works through the ghrelin receptor, and one is an untested combination of both. Reading them side by side clarifies what each receptor pathway actually contributes and how much, or how little, direct evidence backs each claim. Each compound has its own page; a comparison page lines all four up together; and a single shared references list aggregates every source used across the site.

One of the four — tesamorelin — is an FDA-approved prescription medicine with a real clinical trial program behind it. The other three are unapproved research chemicals. This guide treats all four with the same editorial discipline: it says exactly what was studied, in whom, under what conditions, and how far that evidence honestly reaches. That distinction is not a footnote; it is the entire reason this guide exists.

How this guide is compiled

Three principles govern what appears on this site.

First, every research claim is tied to a numbered citation. Each factual statement traces back to a peer-reviewed journal article, a clinical-trial publication, a government drug-safety monograph, or a peer-reviewed review, collected with DOIs and PubMed links on the references page. Where a finding comes from a review synthesizing other work rather than an original study, that is noted.

Second, the evidence is described at its actual strength, not inflated. A single-dose pharmacology study in 11 healthy volunteers is described as exactly that — not extrapolated into a broader safety or efficacy claim. Where a compound (like CJC-1295/Ipamorelin) has never been tested as a fixed combination, this guide says so directly rather than implying combination-specific trial support that does not exist. Where community anecdotal reports exist, they are labeled as anecdotal and never blended into the cited research record.

Third, the four compound pages are cross-referenced. Because the same underlying biology — the GHRH receptor, the ghrelin receptor, pulsatile GH release, IGF-1 — recurs across all four peptides, the pages link to one another and to the comparison page, so a reader can follow one mechanism across the whole guide.

What it is not

Long Island Peptides is not a pharmacy, a clinic, a telehealth platform, or a vendor of any research chemical or prescription drug. It does not sell, supply, source, or broker anything discussed here, and it has no affiliate or referral relationship with any supplier, pharmaceutical company, or telehealth provider. It does not employ clinicians, diagnose conditions, or recommend a dose, schedule, or route of administration for any person.

Tesamorelin is an approved prescription medicine available only through a licensed medical provider, for its specific approved indication. CJC-1295, ipamorelin, and their combination are unapproved research chemicals with no established human safety or efficacy record outside the pharmacology studies cited on their pages. Readers seeking clinical guidance should consult a licensed healthcare provider in their own jurisdiction. Editorial correspondence — citation corrections, newly published studies, out-of-date regulatory information — can be directed to the contact page; this guide monitors that correspondence but cannot respond to requests for medical advice.